12:18 PM EDT, 08/02/2024 (MT Newswires) -- Tandem Diabetes Care ( TNDM ) shares advanced about 18% in recent Friday trading after the company reported Q2 results that surpassed market expectations and raised its sales guidance for 2024.

The company reported Q2 net loss late Thursday of $0.47 per diluted share, narrowing from a loss of $0.55 a year earlier.

Analysts polled by Capital IQ expected a per-share loss of $0.53.

Sales for the quarter ended June 30 were $221.9 million, up from $195.9 million a year earlier.

Analysts surveyed by Capital IQ expected $206.8 million

Tandem expects Q3 non-GAAP sales of $222 million to $225 million.

For 2024, the company now expects non-GAAP sales of $885 million to $892 million, compared with $868 million previously.

Price: 41.53, Change: +6.32, Percent Change: +17.95